Beneficial effect of Bletilla striata extract solution on zymosan-induced interstitial cystitis in rat

Transcriptome Analysis of Wild Bletilla striata Tubers Across Multiple Years Revealed the Molecular Mechanisms Regulating Polysaccharide Metabolism and Tuber Enlargement

A Bletilla striata (Thunb.) Reichb.f., known as Bai Ji in Chinese, is a plant from the Orchidaceae family that has been used for its medicinal properties for thousands of years in China. B. striata holds significant economic value due to its esteemed medicinal applications. Our study aimed to analyze the transcriptome of wild B. striata tubers across multiple years to understand the molecular mechanisms regulating polysaccharide metabolism and tuber enlargement. We collected wild B. striata samples of different growth ages and analyzed their chemical composition, including total phenols, polysaccharides, alkaloids, and proteins. The results showed that the content of these compounds varied with the growth age of the plants. Our study focused on analyzing the genes associated with growth years and accelerating the seedling growth cycle, which holds immense value for the preservation and optimal utilization of superior B. striata orchid resources. To further investigate the underlying molecular mechanisms, we performed a comprehensive transcriptome analysis to explore gene expression, functional annotation, and regulatory networks related to the development and chemical composition of B. striata tubers. The quality of perennial medicinal herbs is intricately linked to their growth age. Unfortunately, excessive wild resource excavation has resulted in the premature harvesting of these herbs, causing a decline in their overall quality and effectiveness. Our study offers valuable insights into the conservation and utilization of B. striata resources.

Syk/Src/NF-κB axis is essentially targeted in anti-inflammatory and anti-gastritis effects of Bletilla striata ethanol extract

ETHNOPHARMACOLOGICAL RELEVANCE

Traditional herbal medicine books "Shin Rhong Bon Cho Kyung" and "Hyang Yak Jip Sung Bang" mentioned that Bletilla striata (Thunb.) Rchb.f. (Orchidaceae) was often used as a medicinal plant and is used in oriental medicine to treat wounds, inflammatory symptoms, and ulcers in stomach, lung, and skin. However, systematic studies on its value as a promising anti-inflammatory remedy were not fully elucidated yet.

AIM OF THE STUDY

The eventual goal of this paper was to explore anti-inflammatory and anti-gastritis effects of Bletilla striata and its inhibitory mechanism with an ethanol extract of this plant (Bs-EE).

MATERIALS AND METHODS

In vitro study includes nitric oxide (NO) inhibitory test by was Griess assay, cell viability check by MTT assay, mRNA level analysis of inflammatory genes by PCR and RT-PCR, and protein level analysis by Western blotting and CESTA. In vivo analysis was done with a mouse gastritis model triggered by HCl/EtOH. Phytochemical finger printing result was observed by GC/MS-MS.

RESULTS

Our in vitro trials showed that Bs-EE dose-dependently reduced NO production in lipopolysaccharide-, Poly(I:C)-, and Pam3CSK-treated RAW264.7 cells without causing cytotoxicity, as shown by an MTT assay. The levels of inflammation-related genes (iNOS, IL-6, IL-1β) showed meaningful reductions in RT-PCR and real-time PCR. The NF-κB activity enhanced in MyD88-overexpressing HEK293T cells was strongly reduced by Bs-EE. Western blotting results indicated that the Bs-EE suppressed the phosphorylation of IκBα, IKKα/β, AKT, p65, p50, Syk, and Src, which produced anti-inflammatory effects. Both Syk and Src were found to be direct targets of Bs-EE. This extract attenuated the inflammatory effect in a murine acute gastritis model induced by HCl/EtOH.

CONCLUSIONS

These findings suggest that an ethanol extract of Bletilla striata could be developed as a promising natural anti-inflammatory drug or health functional food with NF-κB pathway inhibitory activity.

Medicinal plants and natural products for treating overactive bladder

BACKGROUND

Overactive bladder (OAB) presents a high prevalence of 16-18% worldwide. The pathophysiology of OAB is still poorly understood while effective therapy or countermeasure are very limited. On the other hand, medicinal plants and herbal remedies have been utilized for treating lower urinary tract symptoms (LUTS) in both Eastern and Western cultures since ancient times. In recent years, accumulating progress has also been made in OAB treatment research by using medicinal plants.

METHODS

Relevant literature on the studies of medicinal plants and herbs used to treat OAB was reviewed. The medicinal plants were summarized and categorized into two groups, single-herb medications and herbal formulations.

RESULTS

The present review has summarized current understanding of OAB's pathophysiology, its available treatments and new drug targets. Medicinal plants and natural products which have been used or have shown potential for OAB treatment were updated and comprehensively categorized. Studies on a wide variety of medicinal plants showed promising results, although only a few phytochemicals have been isolated and identified. Until now, none of these herbal compounds have been further developed into clinical therapeutics for OAB.

CONCLUSIONS

This review provides the basis for discovering and designing new phytopharmaceutical candidates with effective and well-tolerated properties to treat OAB. Increasing evidences indicate new strategies with alternative herbal treatment for OAB have high efficacy and safety, showing great promise for their clinical use. Future studies in a rigorously designed controlled manner will be beneficial to further support the eligibility of herbal treatment as OAB therapeutics.

Dual properties of pharmacological activities and preparation excipient: Bletilla striata polysaccharides

Bletilla striata has been used for thousands of years and shows the functions of stopping bleeding, reducing swelling, and promoting healing in traditional applications. For Bletilla striata, Bletilla striata polysaccharides (BSP) is the main active ingredient, exhibiting biological functions of anti-inflammatory, anti-oxidant, anti-fibrotic, immune modulation, anti-glycation, and so on. In addition, BSP has exhibited the characteristics of excipient such as bio-adhesion, bio-degradability, and bio-safety and has been prepared into a series of preparations such as nanoparticles, microspheres, microneedles, hydrogels, etc. BSP, as both a drug and an excipient, has already aroused more and more attention. In this review, publications in recent years related to the extraction and identification, biological activities, and excipient application of BSP are reviewed. Specifically, we focused on the advances in the application of BSP as a formulation excipient. We hold opinion that BSP not only needed more researches in the mechanisms, but also the development into hydrogels, nano-formulations, tissue engineering, and so on. And we believe that this paper provides a beneficial reference for further BSP innovation and in-depth research and promotes the use of these natural products in pharmaceutical applications.

Animal models of interstitial cystitis/bladder pain syndrome

Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) is a chronic disorder characterized by pelvic and/or bladder pain, along with lower urinary tract symptoms that have a significant impact on an individual's quality of life. The diverse range of symptoms and underlying causes in IC/BPS patients pose a significant challenge for effective disease management and the development of new and effective treatments. To facilitate the development of innovative therapies for IC/BPS, numerous preclinical animal models have been developed, each focusing on distinct pathophysiological components such as localized urothelial permeability or inflammation, psychological stress, autoimmunity, and central sensitization. However, since the precise etiopathophysiology of IC/BPS remains undefined, these animal models have primarily aimed to replicate the key clinical symptoms of bladder hypersensitivity and pain to enhance the translatability of potential therapeutics. Several animal models have now been characterized to mimic the major symptoms of IC/BPS, and significant progress has been made in refining these models to induce chronic symptomatology that more closely resembles the IC/BPS phenotype. Nevertheless, it's important to note that no single model can fully replicate all aspects of the human disease. When selecting an appropriate model for preclinical therapeutic evaluation, consideration must be given to the specific pathology believed to underlie the development of IC/BPS symptoms in a particular patient group, as well as the type and severity of the model, its duration, and the proposed intervention's mechanism of action. Therefore, it is likely that different models will continue to be necessary for preclinical drug development, depending on the unique etiology of IC/BPS being investigated.

A Systematic Review of Therapeutic Approaches Used in Experimental Models of Interstitial Cystitis/Bladder Pain Syndrome

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a multifactorial, chronic bladder disorder with limited therapeutic options currently available. The present review provides an extensive overview of therapeutic approaches used in in vitro, ex vivo, and in vivo experimental models of IC/BPS. Publications were identified by electronic search of three online databases. Data were extracted for study design, type of treatment, main findings, and outcome, as well as for methodological quality and the reporting of measures to avoid bias. A total of 100 full-text articles were included. The majority of identified articles evaluated therapeutic agents currently recommended to treat IC/BPS by the American Urological Association guidelines (21%) and therapeutic agents currently approved to treat other diseases (11%). More recently published articles assessed therapeutic approaches using stem cells (11%) and plant-derived agents (10%), while novel potential drug targets identified were proteinase-activated (6%) and purinergic (4%) receptors, transient receptor potential channels (3%), microRNAs (2%), and activation of the cannabinoid system (7%). Our results show that the reported methodological quality of animal studies could be substantially improved, and measures to avoid bias should be more consistently reported in order to increase the value of preclinical research in IC/BPS for potential translation to a clinical setting.